PROFILPELAJAR.COM

Foscenvivint

Foscenvivint
Clinical data
Other namesPRI 724; OP 724
Legal status
Legal status
  • Investigational
Identifiers
  • [4-[[(6S,9S,9aS)-1-(Benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)-3,6,9,9a-tetrahydropyrazino[2,1-c][1,2,4]triazin-6-yl]methyl]phenyl] dihydrogen phosphate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC33H35N6O7P
Molar mass658.652 g·mol−1
3D model (JSmol)
  • C[C@H]1[C@H]2N([C@H](C(=O)N1CC3=CC=CC4=C3N=CC=C4)CC5=CC=C(C=C5)OP(=O)(O)O)C(=O)CN(N2C(=O)NCC6=CC=CC=C6)C
  • InChI=1S/C33H35N6O7P/c1-22-31-38(29(40)21-36(2)39(31)33(42)35-19-24-8-4-3-5-9-24)28(18-23-13-15-27(16-14-23)46-47(43,44)45)32(41)37(22)20-26-11-6-10-25-12-7-17-34-30(25)26/h3-17,22,28,31H,18-21H2,1-2H3,(H,35,42)(H2,43,44,45)/t22-,28-,31-/m0/s1
  • Key:VHOZWHQPEJGPCC-AZXNYEMZSA-N

Foscenvivint (PRI 724 or OP 724)[1] is a CREB-binding protein/β-catenin inhibitor that is developed for the treatment of liver diseases[2] such as primary biliary cholangitis,[3] hepatocellular carcinoma,[4][5] and hepatitis C and B virus-induced liver cirrhosis.[6][7]

References

  1. ^ "Foscenvivint - PRISM Pharma Co - AdisInsight". adisinsight.springer.com. Retrieved 23 November 2023.
  2. ^ Ouchi, Hirofumi; Mizutani, Yuki; Yoshimura, Kaori; Sato, Yasunori; Kimura, Kiminori; Haruyama, Yushi; Harada, Kenichi (June 2023). "Anti-inflammatory and antifibrotic effects of CBP/β-catenin inhibitor for hepatocytes: small molecular inhibitor, OP-724 possibly improves liver function". Medical Molecular Morphology. 56 (2): 94–105. doi:10.1007/s00795-022-00343-8. PMID 36645521. S2CID 255847780.
  3. ^ Kimura, Masamichi; Ogawa, Eiichi; Harada, Kenichi; Imamura, Jun; Saio, Masanao; Ikura, Yoshihiro; Yatsuhashi, Hiroshi; Murata, Kazumoto; Miura, Kouichi; Ieiri, Ichiro; Tanaka, Atsushi; Kimura, Kiminori (1 November 2022). "Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study". BMJ Open Gastroenterology. 9 (1) e001001. doi:10.1136/bmjgast-2022-001001. ISSN 2054-4774. PMC 9710334. PMID 36442892.
  4. ^ El-Khoueiry, Anthony B.; Ning, Yan; Yang, Dongyun; Cole, Sarah; Kahn, Michael; Zoghbi, Marwan; Berg, Jennifer; Fujimori, Masamoto; Inada, Tetsuhi; Kouji, Hiroyuki; Lenz, Heinz-Josef (20 May 2013). "A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors". Journal of Clinical Oncology. 31 (15_suppl): 2501. doi:10.1200/jco.2013.31.15_suppl.2501.
  5. ^ Gabata, Ryosuke; Harada, Kenichi; Mizutani, Yuki; Ouchi, Hirofumi; Yoshimura, Kaori; Sato, Yasunori; Kitao, Azusa; Kimura, Kiminori; Kouji, Hiroyuki; Miyashita, Tomoharu; Tajima, Hidehiro; Ohta, Tetsuo (September 2020). "Anti-tumor Activity of the Small Molecule Inhibitor PRI-724 Against β-Catenin-activated Hepatocellular Carcinoma". Anticancer Research. 40 (9): 5211–5219. doi:10.21873/anticanres.14524. PMID 32878809.
  6. ^ Kimura, Kiminori; Kanto, Tatsuya; Shimoda, Shinji; Harada, Kenichi; Kimura, Masamichi; Nishikawa, Koji; Imamura, Jun; Ogawa, Eiichi; Saio, Masanao; Ikura, Yoshihiro; Okusaka, Takuji; Inoue, Kazuaki; Ishikawa, Tetsuya; Ieiri, Ichiro; Kishimoto, Junji; Todaka, Koji; Kamisawa, Terumi (June 2022). "Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study". eBioMedicine. 80 104069. doi:10.1016/j.ebiom.2022.104069. PMC 9126795. PMID 35605429.
  7. ^ Kimura, Kiminori; Ikoma, Akemi; Shibakawa, Maki; Shimoda, Shinji; Harada, Kenichi; Saio, Masanao; Imamura, Jun; Osawa, Yosuke; Kimura, Masamichi; Nishikawa, Koji; Okusaka, Takuji; Morita, Satoshi; Inoue, Kazuaki; Kanto, Tatsuya; Todaka, Koji; Nakanishi, Yoichi; Kohara, Michinori; Mizokami, Masashi (September 2017). "Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial". eBioMedicine. 23: 79–87. doi:10.1016/j.ebiom.2017.08.016. PMC 5605374. PMID 28844410.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.